LL schreef op 11 mei 2022 10:58:
Takeda HAE highlights Q1 2022In Rare Genetics & Hematology, Takeda focuses on several areas of high unmet medical need. In hereditary angioedema,
Takeda aspires to transform the treatment paradigm, including through TAKHZYRO, with continued investment in lifecycle
management programs including evaluating TAKHZYRO in Bradykinin-mediated angioedema with normal C1-inhibitor.
Revenue in Hereditary Angioedema (“HAE”) was 153.6 billion JPY, a year-on-year increase of 14.3 billion JPY, or 10.2%.
Sales of TAKHZYRO were 103.2 billion JPY, an increase of 16.5 billion JPY, or 19.1%, versus the previous fiscal year
primarily due to expansion of the prophylactic market, continued geographic expansion and strong patient uptake. Sales of
CINRYZE decreased by 2.6 billion JPY, or 11.8%, to 19.3 billion JPY, primarily due to conversion to TAKHZYRO and a
shift to newer agents marketed by competitors.
bron:
www.takeda.com/499b9a/siteassets/syst...